Humanized monoclonal antibody (mAb)

Cat.No.	Name	Information
M10111	Anti-human CD3 mAb	CD3 is an important marker of T cells, it is composed of five polypeptide chains: γ, δ, ε, ζ, and η.
M9416	Durvalumab	Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1.
M9236	Ranibizumab	Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A.
M8984	Denosumab	Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption.
M6224	Etanercept	Etanercept is a dimeric fusion protein consisting of two ligand-binding domains of human p75 tumor necrosis factor receptor and the human IgG1 Fc portion.
M6223	Tocilizumab	Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.
M6222	Adalimumab	Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD.
M6221	Pertuzumab	Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
M6219	Rituximab	Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
M6218	Trastuzumab	Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
M6166	Bevacizumab	Humanized vascular endothelial growth factor (VEGF) antibody (bevacizumab; Avastin) is a highly effective monoclonal antibody against metastatic colorectal cancer and several other advanced late stage cancers.
M6104	Ipilimumab	Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
M6103	Cetuximab	Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.
M6102	Pembrolizumab	Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. The binding of PD-1 with pembrolizumab was located on the C'D loop of PD-1. MW : 146.286 KD.
M6101	Atezolizumab	Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
M6100	Nivolumab	Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
M3849	Aflibercept	Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF).
M3847	Alemtuzumab	Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible.
M3835	Alirocumab	Alirocumab is a human monoclonal antibody of the IgG1 isotype, known as PCSK9 inhibitor.
M3814	Sarilumab	Sarilumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptors (IL-6R), thus inhibiting the IL-6-mediated signaling.
M3813	Avelumab (MSB0010718C)	Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1
M1629	Ramucirumab	Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D).
M1622	Secukinumab	Secukinumab is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A.
M1621	Ustekinumab	Ustekinumab is a human monoclonal antibody directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
M1618	Vedolizumab	Vedolizumab is a monoclonal antibody binds to integrin α4β7.
M1616	Daratumumab	Daratumumab is an IgG1k monoclonal antibody directed against CD38.
M1615	Obinutuzumab	Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20.
M1598	Eculizumab	Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5.
M1595	Evolocumab	Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).
M1545	Infliximab	Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
M1539	Omalizumab	Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) and to membrane-bound form of IgE (mIgE).
M1527	Ofatumumab	Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation.
M1519	Matuzumab	Matuzumab is a humanized monoclonal antibody, binds to the epidermal growth factor receptor (EGFR) with high affinity.
M1512	Nimotuzumab	Nimotuzumab is a humanized monoclonal antibody binds to the epidermal growth factor receptor (EGFR). Nimotuzumab recognize the human EGFR but not the murine counterpart.
M1503	Panitumumab	Panitumumab is a fully human monoclonal antibody specific to the epidermal growth factor receptor (EGFR).

Catalog

Signaling Pathways

Product Type

Humanized monoclonal antibody (mAb)

Get to Know Us

Customer Support

Resources

Contact Us